Renal Allograft Tolerance Through Mixed Chimerism
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Rituximab (Primary) ; Siplizumab (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 12 Dec 2013 Planned end date changed from 1 Aug 2016 to 1 Oct 2018 as reported by ClinicalTrials.gov.
- 01 Mar 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 08 Feb 2013 New trial record